GenCore version 5.1.3

OM protein - nucleic search, using frame_plus_p2n model

Run on: January 16, 2003, 16:51:22 ; Search time 212.829 Seconds
(without alignments)
137.557 Million cell updates/sec

Title: US-09-856-070-19
Perfect score: 65
Sequence: 1 KEELMERLQDYEE 13

Scoring table: BLOSUM62
Xgapop 10.0 , Xgapext 0.5
Ygapop 10.0 , Ygapext 0.5
Fgapop 6.0 , Fgapext 7.0
Delop 6.0 , Delext 7.0

Searched: 2185239 seqs, 1125999159 residues

Total number of hits satisfying chosen parameters: 4370478

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Command line parameters:
-MODEL=frame+_p2n model -DEV=xlp
-Q=/cgn2_1/USPTO_spool/US09856070/runat_14012003_155833_1611/app_query.fasta_1 1592
-DB=N_Geneseq_101002 -QFMT=fasta_p -SUFFIX=rng -MINMATCH=0.1 -LOOPCL=0
-LOOPEXT=0 -UNITS=bits -START=1 -END=-1 -MATRIX=blosum62 -TRANS=human40.cdi
-LIST=45 -DOCALIGN=200 -THR_SCORE=pct -THR_MAX=100 -THR_MIN=0 -ALIGN=15
-MODE=LOCAL -OUTFMT=ptb -NORM=ext -HEAPSIZE=500 -MINLEN=0 -MAXLEN=2000000000
-USER=US09856070_@CGN_1_1_448_@runat_14012003_155833_1611 -NCPU=6 -IOPU=3
-NO_XLPXY -NO_MMAP -LAPGEQUERY -NEG_SCORES=0 -WAIT -LONGCL=0 -DEV_TIMEOUT=120
-WARN_TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.5 -YGAPOP=10
-YGAPEXT=0.5 -FGAPOP=6 -DELOP=6 -DELEXT=7

Database : N_Geneseq_101002:*
1: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1980.DAT:*
2: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1981.DAT:*
3: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1982.DAT:*
4: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1983.DAT:*
5: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1984.DAT:*
6: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1985.DAT:*
7: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1986.DAT:*
8: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1987.DAT:*
9: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1988.DAT:*
10: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1989.DAT:*
11: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1990.DAT:*
12: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1991.DAT:*
13: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1992.DAT:*
14: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1993.DAT:*
15: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1994.DAT:*
16: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1995.DAT:*
17: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1996.DAT:*
18: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1997.DAT:*
19: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1998.DAT:*
20: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1999.DAT:*
21: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA2000.DAT:*
22: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA2001A.DAT:*
23: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA2001B.DAT:*
24: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.		Score	Query Match	Length	DB	ID	Description
1		65	100.0	2595	22	AAH33385	Human colon cancer
2		65	100.0	2930	24	ABQ88181	Human osteoblast d
3		65	100.0	2930	24	ABK70285	Human lung cancer
4		65	100.0	3044	24	ABQ88180	Human osteoblast d
5		65	100.0	3044	24	ABK84552	Human cDNA differe
6		65	100.0	3044	24	ABN97223	Gene #2721 used to
7		65	100.0	3047	24	ABK09792	Human ovarian tumo
8		65	100.0	3072	24	ABQ88182	Human osteoblast d
9		65	100.0	3115	21	AAC98113	Human colon cancer
c	10	65	100.0	11445	22	AAK70537	Human immune/haema
11		41	63.1	1447	23	AAS93352	DNA encoding novel
c	12	41	63.1	66491	24	ABQ88140	Human osteoblast d
c	13	40	61.5	224	22	ABA74089	Human foetal liver
c	14	40	61.5	224	22	AAK22545	Human brain expres
c	15	40	61.5	520	22	ABA61592	Human foetal liver
c	16	40	61.5	523	22	AAK09895	Human brain expres
17		40	61.5	1815	23	AAS80764	DNA encoding novel
18		40	61.5	2528	21	AAA78410	Human secreted pro
19		40	61.5	2701	22	AAH14497	Human cDNA sequenc
20		40	61.5	2901	24	ABQ54268	Human ovarian anti
21		40	61.5	2979	23	ABV25470	Human prostate exp
22		40	61.5	4226	23	AAS84124	DNA encoding novel
23		40	61.5	4558	22	AAH72780	Human cervical can
c	24	40	61.5	149671	24	ABK84797	Human cDNA differe
c	25	39	60.0	205	22	ABA71189	Human foetal liver
c	26	39	60.0	205	22	AAK19487	Human brain expres
c	27	39	60.0	205	22	AAK45478	Human bone marrow
c	28	39	60.0	205	22	AAI51423	Probe #20109 used
c	29	39	60.0	205	24	ABS10746	Human genome deriv
c	30	39	60.0	452	22	ABA58691	Human foetal liver
c	31	39	60.0	452	22	AAK06826	Human brain expres
c	32	39	60.0	452	22	AAK32544	Human bone marrow
c	33	39	60.0	452	22	AAI38870	Probe #7056 used t
c	34	39	60.0	452	24	ABS07334	Human genome deriv
35		39	60.0	525	21	AAC18855	Human secreted pro
36		39	60.0	553	24	ABL38620	Human colon tumour
c	37	39	60.0	692	22	AAS43034	DNA encoding G pro
38		39	60.0	1256	21	AAF21134	Human low adenosin
39		39	60.0	1256	21	AAA35012	Human adenosine re
40		39	60.0	1400	13	AAQ31436	Encodes a HeLa cel
41		39	60.0	1488	15	AAQ56910	DNA encoding a qly
42		39	60.0	1867	22	AAH34246	Human colon cancer
43		39	60.0	1985	23	AAS83233	DNA encoding novel
44		39	60.0	2134	18	AAI59566	Human myeloid deri
45		39	60.0	2142	23	AAS83235	DNA encoding novel

ALIGNMENTS

RESULT 1
AAH33385
ID AAH33385 standard; cDNA; 2595 BP.
XX
AC AAH33385;
XX
DT 03-SEP-2001 (first entry)
XX
DE Human colon cancer antigen encoding cDNA SEQ ID NO:441.
XX
KW Human; colon cancer; cancer antigen; diagnosis; detection;
KW colorectal carcinoma; ss.
XX
OS Homo sapiens.
XX
PN WO200122920-A2.
XX
PD 05-APR-2001.

```
XX
PF   28-SEP-2000; 2000WO-US26524.
XX
PR   29-SEP-1999;   99US-0157137
PR   03-NOV-1999;   99US-0163280.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Ruben SM,  Barash SC,  Birse CE,  Rosen CA;
XX
DR   WPI; 2001-235357/24.
DR   P-PSDB; AAG73954.
XX
PT   Nucleic acids encoding 4277 human colon cancer-associated polypeptides,
PT   useful for preventing, diagnosing and/or treating colorectal cancers -
XX
PS   Claim 1; Page 2539-2540; 9803pp; English.
XX
CC   AAH32943 to AAH37195 and AAG73514 to AAG77788 represent human colon
CC   cancer-associated nucleic acid molecules (N) and proteins (P), where
CC   the proteins are collectively known as colon cancer antigens. The colon
CC   cancer antigens have cytostatic activity and can be used in gene
CC   therapy and vaccine production. N and P may be used in the prevention,
CC   diagnosis and treatment of diseases associated with inappropriate P
CC   expression. For example, N and P may be used to treat disorders
CC   associated with decreased expression by rectifying mutations or deletions
CC   in a patient's genome that affect the activity of P by expressing
CC   inactive proteins or to supplement the patients own production of P.
CC   Additionally, N may be used to produce the colon cancer-associated Ps,
CC   by inserting the nucleic acids into a host cell and culturing the cell
CC   to express the proteins. N and P can be used in the prevention, diagnosis
CC   and treatment of colorectal carcinomas and cancers. AAH37196 to AAH37204
CC   and AAB77789 represent sequences used in the exemplification of the
CC   present invention.
CC   N.B. Pages 666 to 682 and page 7053 of the sequence listing were
CC   missing at time of publication, meaning no sequences are present for
CC   SEQ ID NO:1027 to 1052, 7921 and 7922.
XX
SQ   Sequence 2595 BP; 742 A; 562 C; 714 G; 567 T; 10 other;

Alignment Scores:
Pred. No.:                0.00473         Length:          2595
Score:                    65.00           Matches:         13
Percent Similarity:       100.00%         Conservative:    0
Best Local Similarity:    100.00%         Mismatches:      0
Query Match:              100.00%         Indels:          0
DB:                       22              Gaps:            0

US-09-856-070-19 (1-13) x AAH33385 (1-2595)

Qy       1 LysGluGluLeuMetLeuArgLeuGlnAspTyrGluGlu 13
          |||||||||||||||||||||||||||||||||||||||||
Db     658 AAGGAGGAGTTGATGCTGCGGCTGCAGGACTATGAGGAG 696

RESULT 2
ABQ88181
ID   ABQ88181 standard; cDNA; 2930 BP.
XX
AC   ABQ88181;
XX
DT   18-SEP-2002  (first entry)
XX
DE   Human osteoblast differentiation related cDNA SEQ ID NO 88.
XX
KW   Human; osteoblast; stem cell differentiation; bone tissue deposition;
KW   osteoporosis; osteopathic; ss.
XX
OS   Homo sapiens.
XX
PN   WO200250301-A2
XX
PD   27-JUN-2002.
XX
PF   18-DEC-2001; 2001WO-US48276.
XX
PR   18-DEC-2000; 2000US-255882P.
PR   24-APR-2001; 2001US-286691P.
XX
PA   (GENE-) GENE LOGIC INC.
PA   (PROC ) PROCTER & GAMBLE CO.
XX
PI   Ji D,  Axelrod DW,  Cook JS,  Jaiswal N,  Einstein R,  Houghton A;
PI   Mertz L;
XX
DR   WPI; 2002-557663/59.
XX
PT   Use of genes and their expression profiles associated with osteoblast
PT   differentiation for screening modulators bone formation, for diagnosing
PT   or treating e.g. osteoporosis, or as markers for the differentiation
PT   process -
XX
PS   Claim 1, SEQ ID NO 88, 78pp + Sequence Listing; English.
XX
CC   The invention relates to genes and their expression profiles are used
CC   for.
CC   (a) screening modulators of precursor stem cell differentiation into
CC   osteoblasts, or bone tissue deposition;
CC   (b) diagnosing abnormal deposition of bone tissue, abnormal rate of
CC   osteoblast formation or osteoporosis; or
CC   (c) treating or monitoring treatment of the conditions cited in (b), or
CC   monitoring the progression of bone tissue deposition.
CC   Specific conditions include postmenopausal osteoporosis, glucocorticoid
CC   osteoporosis or male osteoporosis, osteopenia, osteodystrophy,
CC   drug-induced abnormalities in bone formation or bone loss, conditions
CC   that involve altered bone metabolism (e.g. idiopathic juvenile
CC   osteoporosis), skeletal disease linked to breast cancer, mastocytosis,
CC   Fanconi syndrome or fibrous dysplasia. The present sequence is that of an
CC   osteoblast differentiation associated cDNA marker of the invention.
CC   Note. The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 2930 BP; 793 A; 658 C; 821 G; 658 T; 0 other;

Alignment Scores:
Pred. No.:                0.00545         Length:          2930
Score:                    65.00           Matches:         13
Percent Similarity:       100.00%         Conservative:    0
Best Local Similarity:    100.00%         Mismatches:      0
Query Match               100.00%         Indels.          0
DB:                       24              Gaps:            0

US-09-856-070-19 (1-13) x ABQ88181 (1-2930)

Qy       1 LysGluGluLeuMetLeuArgLeuGlnAspTyrGluGlu 13
          |||||||||||||||||||||||||||||||||||||||||
Db    1106 AAGGAGGAGTTGATGCTGCGGCTGCAGGACTATGAGGAG 1144

RESULT 3
ABK70285
ID   ABK70285 standard; cDNA; 2930 BP.
XX
AC   ABK70285;
XX
DT   15-JUL-2002  (first entry)
XX
DE   Human lung cancer associated full length cDNA DMSM-51.
XX
KW   Human, ss, gene, lung cancer, cytostatic; tumour; vaccine.
XX
OS   Homo sapiens.
XX
PN   WO200224057-A2
XX
PD   28-MAR-2002.
XX
```

PF 20-SEP-2001; 2001WO-US42232.
XX
PR 22-SEP-2000; 2000US-234837P
PR 10-OCT-2000; 2000US-239440P.
PR 29-JUN-2001; 2001US-301928P.
XX
PA (CORI-) CORIXA CORP.
XX
PI Benson DR, Mohamath R, Lodes MJ;
XX
DR WPI; 2002-372001/40
XX
PT New tumour lung proteins and nucleic acids encoding the proteins, useful
PT as vaccines and for treating, preventing, diagnosing or monitoring lung
PT cancer -
XX
PS Claim 1; Page 159-160, 189pp; English.
XX
CC The invention relates to an isolated polynucleotide comprising a sequence
CC selected from 183 human DNA sequences (appearing as ABK70130-ABK70312),
CC or their fragments, homologues, variants or complements and their encoded
CC polypeptides. Also included are an expression vector comprising the
CC polynucleotide operably linked to an expression control sequence; a host
CC cell transformed or transfected with an expression vector of; an isolated
CC antibody, or its antigen-binding fragment that specifically binds to the
CC polypeptide; a method for detecting the presence of a cancer in a
CC patient; a fusion protein comprising at least the polypeptide; an
CC oligonucleotide that hybridises to the polynucleotide under moderately
CC stringent conditions; a method for stimulating and/or expanding T cells
CC specific for a tumour protein; an isolated T cell population comprising T
CC cells prepared from the method of above; a composition comprising a first
CC component consisting of carriers and immunostimulants, and a second
CC component selected from the polynucleotides, proteins, antibodies, fusion
CC proteins, T cell populations and antigen presenting cells expressing the
CC polypeptide; methods for stimulating an immune response or treating
CC cancer in a patient by administering the composition and diagnostic kits
CC comprising at least one of the oligonucleotide of, or an antibody and a
CC detection reagent consisting of a reporter group. The polypeptides and
CC polynucleotides are useful as vaccines for the treatment or prevention of
CC lung cancer, and for diagnosis and monitoring of such cancer. The
CC polynucleotide, polypeptide and antigen presenting cells can be
CC used to stimulate or expand T cells specific for a tumorous protein.
CC The polynucleotides may be used as probes or primers for nucleic acid
CC hybridisation, and in the preparation of ribozyme molecules for
CC inhibiting expression of tumour polypeptides and proteins in tumour
CC cells. The present sequence is one of the 183 lung cancer associated
CC polynucleotides.
XX
SQ Sequence 2930 BP; 793 A; 658 C; 821 G; 658 T; 0 other;

Alignment Scores:

Pred. No.:	0.00545	Length:	2930
Score:	65.00	Matches:	13
Percent Similarity:	100.00%	Conservative:	0
Best Local Similarity:	100.00%	Mismatches:	0
Query Match:	100.00%	Indels:	0
DB:	24	Gaps:	0

US-09-856-070-19 (1-13) x ABK70285 (1-2930)

```
Qy       1 LysGluGluLeuMetLeuArgLeuGlnAspTyrGluGlu 13
           ||||||||||||||||||||||||||||||||||||||||
Db    1106 AAGGAGGAGTTGATGCTGCGGCTGCAGGACTATGAGGAG 1144
```

RESULT 4
ABQ88180
ID ABQ88180 standard; cDNA; 3044 BP.
XX
AC ABQ88180;
XX
DT 18-SEP-2002 (first entry)
XX
DE Human osteoblast differentiation related cDNA SEQ ID NO 87.
XX
KW Human, osteoblast, stem cell differentiation; bone tissue deposition;
KW osteoporosis; osteopathic; ss.
XX
OS Homo sapiens.
XX
PN WO200250301 A2.
XX
PD 27-JUN-2002.
XX
PF 18-DEC-2001; 2001WO-US48876.
XX
PR 18-DEC-2000; 2000US-255882P.
PR 24-APR-2001; 2001US-285691P.
XX
PA (GENE-) GENE LOGIC INC.
PA (PROC) PROCTER & GAMBLE CO.
XX
PI Ji D, Axelrod DW, Cook JS, Jaiswal N, Einstein R, Houghton A;
PI Mertz L;
XX
DR WPI; 2002-557663/59.
XX
PT Use of genes and their expression profiles associated with osteoblast
PT differentiation for screening modulators bone formation, for diagnosing
PT or treating e.g. osteoporosis, or as markers for the differentiation
PT process -
XX
PS Claim 1; SEQ ID NO 87; 78pp + Sequence Listing; English.
XX
CC The invention relates to genes and their expression profiles are used
CC for:
CC (a) screening modulators of precursor stem cell differentiation into
CC osteoblasts, or bone tissue deposition;
CC (b) diagnosing abnormal deposition of bone tissue, abnormal rate of
CC osteoblast formation or osteoporosis; or
CC (c) treating or monitoring treatment of the conditions cited in (b), or
CC monitoring the progression of bone tissue deposition.
CC Specific conditions include postmenopausal osteoporosis, glucocorticoid
CC osteoporosis or male osteoporosis, osteopenia, osteodystrophy,
CC drug-induced abnormalities in bone formation or bone loss, conditions
CC that involve altered bone metabolism (e.g. idiopathic juvenile
CC osteoporosis), skeletal disease linked to breast cancer, mastocytosis,
CC Fanconi syndrome or fibrous dysplasia. The present sequence is that of an
CC osteoblast differentiation associated cDNA marker of the invention.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 3044 BP; 826 A; 687 C; 855 G; 675 T; 1 other;

Alignment Scores:

Pred. No.:	0.0057	Length:	3044
Score:	65.00	Matches:	13
Percent Similarity:	100.00%	Conservative:	0
Best Local Similarity:	100.00%	Mismatches:	0
Query Match:	100.00%	Indels:	0
DB:	24	Gaps:	0

US-09-856-070-19 (1-13) x ABQ88180 (1-3044)

```
Qy       1 LysGluGluLeuMetLeuArgLeuGlnAspTyrGluGlu 13
           ||||||||||||||||||||||||||||||||||||||||
Db    1147 AAGGAGGAGTTGATGCTGCGGCTGCAGGACTATGAGGAG 1185
```

RESULT 5
ABK84552
ID ABK84552 standard; cDNA; 3044 BP.
XX
AC ABK84552;
XX
DT 14-AUG-2002 (first entry)
XX

DE Human cDNA differentially expressed in granulocytic cells #1123.
XX
KW Human, ss; granulocytic cell; DNA chip; bacterial infection;
KW viral infection; parasitic infection; protozoal infection;
KW fungal infection; sterile inflammatory disease; psoriasis;
KW rheumatoid arthritis; glomerulonephritis; asthma; thrombosis;
KW cardiac reperfusion injury; renal reperfusion injury; ARDS;
KW adult respiratory distress syndrome, inflammatory bowel disease;
KW Crohn's disease; ulcerative colitis; periodontal disease;
KW granulocyte activation; chronic inflammation; allergy.
XX
OS Homo sapiens.
XX
PN WO200228999-A2.
XX
PD 11-APR-2002.
XX
PF 03-OCT-2001; 2001WO-US30821.
XX
PR 03-OCT-2000; 2000US-237189P.
XX
PA (GENE-) GENE LOGIC INC.
XX
PI Beazer Barclay Y, Weissman SM, Yamaga S, Vockley J;
XX
DR WPI; 2002-435328/46
XX
PT Detecting granulocyte activation by detecting differential expression
PT of genes associated with granulocyte activation, which serves as
PT diagnostic markers that is useful for monitoring disease states and
PT drug toxicity -
XX
PS Claim 1; SEQ ID No 1123; 114pp; English.
XX
CC The invention relates to detecting (M1) granulocyte (GC) activation
CC (GCA), by detecting the level of expression of gene(s) (Gs) identified by
CC DNA chip analysis as given in the specification, and comparing
CC the expression level to an expression level in an unactivated
CC GC, where differential expression of Gs is indicative of GCA.
CC Also included are modulating (M2) GA by contacting GC with an agent
CC that alters the expression of at least one gene in Gs; (2) screening (M3)
CC for an agent capable of modulating GCA or an inflammation (especially
CC chronic) in a tissue, an allergic response in a subject, exposure of a
CC subject to a pathogen or sterile inflammatory disease using the
CC gene expression profile; (3) detecting (M4) an inflammation (especially
CC chronic) in a tissue, an allergic response in a subject, exposure of a
CC subject to a pathogen or sterile inflammatory disease, by detecting the
CC level of expression in a sample of the tissue of gene(s) from Gs, where
CC the level of expression of the gene is indicative of inflammation;
CC (4) treating (M5) an inflammation (especially chronic) or in a tissue,
CC an allergic response in a subject, exposure of a subject to a pathogen
CC or sterile inflammatory disease, by contacting a tissue having
CC inflammation with an agent that modulates the expression of gene(s)
CC from Gs in the tissue. M1 is useful for detecting GCA; M2 is useful for
CC modulating GA; M3 is useful for screening an agent capable of modulating
CC GCA preferably in an inflammation in a tissue, M4 is useful for
CC detecting an inflammation (especially chronic) in a tissue, an allergic
CC response in a subject, exposure of a subject to a pathogen or sterile
CC inflammatory disease (e.g. psoriasis, rheumatoid arthritis,
CC glomerulonephritis, asthma, thrombosis, cardiac reperfusion injury, renal
CC reperfusion injury, ARDS, adult respiratory distress syndrome,
CC inflammatory bowel disease, Crohn's disease, ulcerative colitis,
CC periodontal disease, also bacterial infection, viral infection,
CC parasitic infection, protozoal infection, fungal infection and M5 is
CC useful for treating one of the above conditions The present
CC sequence represents a gene differentially expressed in granulocytes.
CC Note: The sequence data for this patent did not form part
CC of the printed specification, but was obtained in electronic
CC format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 3044 BP; 826 A; 687 C; 855 G; 675 T; 1 other;

Alignment Scores:
Pred No.: 0.0057 Length: 3044
Score: 65.00 Matches: 13
Percent Similarity 100.00% Conservative: 0
Best Local Similarity: 100.00% Mismatches: 0
Query Match: 100.00% Indels: 0
DB: 24 Caps: 0

US-09-856-070-19 (1-13) x ABK84552 (1-3044)

Qy 1 LysGluGluLeuMetLeuArgLeuGlnAspTyrGluGlu 13
||||||||||||||||||||||||||||||||||||||||||||
Db 1147 AAGGAGGAGTTGATGCTGCGGCTGCAGGACTATGAGGAG 1185

RESULT 6
ABN97223
ID ABN97223 standard; DNA; 3044 BP.
XX
AC ABN97223;
XX
DT 13-AUG-2002 (first entry)
XX
DE Gene #3721 used to diagnose liver cancer.
XX
KW Gene, liver cancer, ds, hepatocellular carcinoma, hepatotropic;
KW metastatic liver tumour, cytostatic, expression profile; disease state;
KW disease progression; drug toxicity; drug efficacy; drug metabolism.
XX
OS Homo sapiens.
XX
PN WO200229103-A2.
XX
PD 11-APR-2002.
XX
PF 02-OCT-2001; 2001WO-US30589.
XX
PR 02-OCT-2000; 2000US-237054P.
XX
PA (GENE-) GENE LOGIC INC.
XX
PI Horne D, Alvares C, Peres-Da-Silva S, Vockley JG;
XX
DR WPI; 2002-426119/45.
XX
PT Diagnosing and detecting the progression of liver cancer,
PT hepatocellular carcinoma or metastatic liver tumor in a patient,
PT involves detecting the level of expression of two or more genes in a
PT liver tissue sample -
XX
PS Claim 1; SEQ ID NO 3721; 298pp; English.
XX
CC The invention relates to a novel method for diagnosing and detecting the
CC progression of liver cancer, hepatocellular carcinoma or metastatic liver
CC tumour in a patient, and differentiating metastatic liver cancer from
CC hepatocellular carcinoma in a patient, involving detecting the level of
CC expression of two or more genes represented in ABN93503-ABN97455 in a
CC tissue sample. The method of the invention has hepatotropic, and
CC cytostatic activity. The method is useful for diagnosing and detecting
CC the progression of liver cancer, hepatocellular carcinoma and metastatic
CC liver carcinoma in a patient. The method is useful for identifying
CC expression profiles which serve as useful diagnostic markers as well as
CC markers that can be used to monitor disease states, disease progression,
CC drug toxicity, drug efficacy and drug metabolism.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 3044 BP; 826 A; 687 C; 855 G; 675 T; 1 other;

Alignment Scores:
Pred. No.: 0.0057 Length: 3044
Score: 65.00 Matches: 13
Percent Similarity: 100.00% Conservative: 0

```
Best Local Similarity:  100.00%        Mismatches:    0
Query Match:            100.00%        Indels:        0
DB:                     24             Gaps:          0

US-09-856-070-19 (1-13) x ABN97223 (1-3044)

Qy       1 LysGluGluLeuMetLeuArgLeuGlnAspTyrGluGlu 13
           |||||||||||||||||||||||||||||||||||||||
Db    1147 AAGGAGGAGTTGATGCTGCGGCTGCAGGACTATGAGGAG 1185

RESULT 7
ABK09792
ID   ABK09792 standard; cDNA; 3047 BP
XX
AC   ABK09792;
XX
DT   14-MAR-2002  (first entry)
XX
DE   Human ovarian tumour protein encoding cDNA #325
XX
KW   Human; ovarian tumour protein, cancer, cytostatic, immunostimulant, ss,
KW   gene therapy; CD4+ T cell, CD8+ T cell, PCR primer.
XX
OS   Homo sapiens.
XX
PN   WO200190154-A2
XX
PD   29-NOV-2001.
XX
PF   23-MAY-2001; 2001WO-US16805
XX
PR   24-MAY-2000; 2000US-207107P
PR   13-JUN-2000; 2000US-211457P
PR   23-JUN-2000; 2000US-213673P
PR   03-AUG-2000; 2000US-223288P
PR   01-MAR-2001; 2001US-272790P
XX
PA   (CORI-) CORIXA CORP.
XX
PI   Xu J,  Mitcham JL,  Harlocker SL,  Dillon DC,  Secrist H,  Lodes MJ;
PI   Algate PA,  Fling SP,  Mannion J,  Benson DR,  Carter D;
XX
DR   WPI; 2002-097641/13
XX
PT   New isolated polynucleotide encoding polypeptide comprising portion of
PT   ovarian tumour protein, useful for detection, diagnosis and therapy of
PT   human ovarian cancer -
XX
PS   Claim 1; Page 269 270; 285pp; English.
XX
CC   The invention relates to an isolated polynucleotide encoding a
CC   polypeptide comprising a portion of an ovarian tumour protein. The
CC   sequences of the invention are useful for stimulating an immune response
CC   and for treating ovarian cancer in a patient. An antigen presenting cell
CC   that expresses the sequences is useful for treating ovarian cancer by
CC   incubating CD4+ and/or CD8+ T cells isolated from a patient. The T cells
CC   can then be proliferated and administered to the patient to inhibit the
CC   development of cancer. The DNA sequences are useful as probes or primers
CC   for nucleic acid hybridisation, to direct expression of a polypeptide in
CC   appropriate host cells. Detecting the presence of a cancer in a patient
CC   involves obtaining a biological sample from the patient, contacting the
CC   biological sample with an agent that binds to the protein, detecting the
CC   amount of protein that binds to the agent, comparing the amount of
CC   protein to a predetermined cut-off value and determining the presence of
CC   cancer. Sequences ABK09464-ABK09802 represent PCR primers and cDNA
CC   molecules encoding ovarian tumour proteins of the invention
XX
SQ   Sequence 3047 BP; 828 A; 687 C; 856 G; 675 T; 1 other;

Alignment Scores:
Pred. No.:              0.0057         Length:        3047
Score:                  65.00          Matches:       13
Percent Similarity:     100.00%        Conservative:  0

Best Local Similarity:  100.00%        Mismatches:    0
Query Match:            100.00%        Indels:        0
DB:                     24             Gaps:          0

US-09-856-070-19 (1-13) x ABK09792 (1-3047)

Qy       1 LysGluGluLeuMetLeuArgLeuGlnAspTyrGluGlu 13
           |||||||||||||||||||||||||||||||||||||||
Db    1147 AAGGAGGAGTTGATGCTGCGGCTGCAGGACTATGAGGAG 1185

RESULT 8
ABQ88182
ID   ABQ88182 standard; cDNA; 3072 BP.
XX
AC   ABQ88182;
XX
DT   18 SEP 2002  (first entry)
XX
DE   Human osteoblast differentiation related cDNA SEQ ID NO 89.
XX
KW   Human, osteoblast, stem cell differentiation, bone tissue deposition;
KW   osteoporosis, osteopathic; ss.
XX
OS   Homo sapiens.
XX
PN   WO200250301-A2.
XX
PD   27-JUN-2002.
XX
PF   18 DEC 2001, 2001WO-US48276.
XX
PR   18-DEC 2000, 2000US-256882P.
PR   24-APR-2001; 2001US-285691P.
XX
PA   (GENE-) GENE LOGIC INC.
PA   (PROC ) PROCTER & GAMBLE CO.
XX
PI   Ji D,  Axelrod DW,  Cook JS,  Jaiswal N,  Einstein R,  Houghton A;
PI   Mertz L;
XX
DR   WPI; 2002-557663/59.
XX
PT   Use of genes and their expression profiles associated with osteoblast
PT   differentiation for screening modulators bone formation, for diagnosing
PT   or treating e.g. osteoporosis, or as markers for the differentiation
PT   process -
XX
PS   Claim 1; SEQ ID NO 89; 78pp + Sequence Listing; English.
XX
CC   The invention relates to genes and their expression profiles are used
CC   for:
CC   (a) screening modulators of precursor stem cell differentiation into
CC   osteoblasts, or bone tissue deposition;
CC   (b) diagnosing abnormal deposition of bone tissue, abnormal rate of
CC   osteoblast formation or osteoporosis; or
CC   (c) treating or monitoring treatment of the conditions cited in (b), or
CC   monitoring the progression of bone tissue deposition.
CC   Specific conditions include postmenopausal osteoporosis, glucocorticoid
CC   osteoporosis or male osteoporosis, osteopenia, osteodystrophy,
CC   drug-induced abnormalities in bone formation or bone loss, conditions
CC   that involve altered bone metabolism (e.g. idiopathic juvenile
CC   osteoporosis), skeletal disease linked to breast cancer, mastocytosis,
CC   Fanconi syndrome or fibrous dysplasia. The present sequence is that of an
CC   osteoblast differentiation associated cDNA marker of the invention.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 3072 BP; 846 A; 688 C; 868 G; 670 T; 0 other;

Alignment Scores:
Pred. No.:              0.00576        Length:        3072
Score:                  65.00          Matches:       13
```

```
Percent Similarity:     100.00%         Conservative:  0
Best Local Similarity:  100.00%         Mismatches:    0
Query Match:            100.00%         Indels:        0
DB:                     24              Gaps:          0

US-09-856-070-19 (1-13) x ABQ88182 (1-3072)

Qy       1 LysGluGluLeuMetLeuArgLeuGlnAspTyrGluGlu 13
           |||||||||||||||||||||||||||||||||||||||
Db    1163 AAGGAGGAGTTGATGCTGCGGCTGCAGGACTATGAGGAG 1201

RESULT 9
AAC98113
ID   AAC98113 standard; cDNA; 3115 BP.
XX
AC   AAC98113;
XX
DT   09-MAR-2001  (first entry)
XX
DE   Human colon cancer antigen nucleotide sequence SEQ ID NO:123.
XX
KW   Human; colon cancer; colon cancer antigen; diagnosis; detection;
KW   identification; cytostatic; cardioactive; neuroprotective; vulnerary;
KW   immunomodulatory; muscular; gynaecological; gastrointestinal;
KW   nephrotropic; antiinfective; antibacterial; gene therapy; wound;
KW   neural disorder; immune system disorder; muscular disorder;
KW   reproductive disorder; gastrointestinal disorder; renal disorder;
KW   infectious disease; cardiovascular disorder; ss.
XX
OS   Homo sapiens.
XX
PN   WO200055351 A1.
XX
PD   21-SEP-2000.
XX
PF   08-MAR-2000; 2000WO-US05883.
XX
PR   12-MAR-1999;   99US-0124270.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Ruben SM;
XX
DR   WPI; 2000-587534/55.
DR   P-PSDB; AAB53356.
XX
PT   Colon cancer associated gene sequences, referred to as colon cancer
PT   antigens, useful for the treatment, prevention, and diagnosis of colon
PT   disorders such as colon cancer -
XX
PS   Claim 1; Page 559-560; 2104pp; English.
XX
CC   AAC97991 to AAC98763 encode the human colon cancer associated proteins
CC   called human colon cancer antigens, given in AAB53234 to AAB54006. The
CC   human colon cancer antigens can have cytostatic, cardioactive, muscular;
CC   neuroprotective, immunomodulatory, gynaecological, gastrointestinal,
CC   vulnerary, nephrotropic, antiinfective and antibacterial activities, and
CC   can be used in gene therapy. The colon cancer antigen polynucleotides,
CC   proteins and antibodies to the proteins are useful for the prevention,
CC   treatment and diagnosis of colon disorders, such as colon cancer. The
CC   polynucleotides may be used in diagnostics and research, such as for
CC   chromosome identification, and as hybridisation probes. The proteins
CC   may also be used to prevent diseases such as neural disorders, immune
CC   system disorders, muscular disorders, reproductive disorders,
CC   gastrointestinal disorders, wounds, renal disorders, infectious
CC   diseases, and cardiovascular disorders. AAC98764 to AAC98772 and
CC   AAB54007 represent sequences used in the exemplification of the present
CC   invention.
XX
SQ   Sequence 3115 BP; 873 A; 696 C; 872 G; 670 T; 4 other;

Alignment Scores:
Pred. No.:              0.00585         Length:         3115

Score:                  65.00           Matches:        13
Percent Similarity:     100.00%         Conservative:  0
Best Local Similarity:  100.00%         Mismatches:    0
Query Match:            100.00%         Indels:        0
DB:                     21              Gaps:          0

US-09-856-070-19 (1-13) x AAC98113 (1-3115)

Qy       1 LysGluGluLeuMetLeuArgLeuGlnAspTyrGluGlu 13
           |||||||||||||||||||||||||||||||||||||||
Db    1179 AAGGAGGAGTTGATGCTGCGGCTGCAGGACTATGAGGAG 1217

RESULT 10
AAK70537/C
ID   AAK70537 standard; DNA; 11445 BP.
XX
AC   AAK70537;
XX
DT   06-NOV-2001  (first entry)
XX
DE   Human immune/haematopoietic antigen genomic sequence SEQ ID NO:25349.
XX
KW   Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
KW   cytostatic; gene therapy; vaccine; metastasis; ds.
XX
OS   Homo sapiens.
XX
PN   WO200157182 A2.
XX
PD   09-AUG-2001.
XX
PF   17-JAN-2001; 2001WO-US01354.
XX
PR   31-JAN-2000; 2000US-0174065.
PR   04-FEB-2000; 2000US-0180628.
PR   24-FEB-2000; 2000US-0184664.
PR   02-MAR-2000; 2000US-0186350.
PR   16-MAR-2000; 2000US-0189874.
PR   17-MAR-2000; 2000US-0190076.
PR   18-APR-2000; 2000US-0198123.
PR   19-MAY-2000; 2000US-0205515.
PR   07-JUN-2000; 2000US-0209467.
PR   28-JUN-2000; 2000US-0214886.
PR   30-JUN-2000; 2000US-0215135.
PR   07-JUL-2000; 2000US-0216647.
PR   07-JUL-2000; 2000US-0216880.
PR   11-JUL-2000; 2000US-0217487.
PR   11-JUL-2000; 2000US-0217496.
PR   14-JUL-2000; 2000US-0218290.
PR   26-JUL-2000; 2000US-0220963.
PR   26-JUL-2000; 2000US-0220964.
PR   14-AUG-2000; 2000US-0224518.
PR   14-AUG-2000; 2000US-0224519.
PR   14-AUG-2000; 2000US-0225213.
PR   14-AUG-2000; 2000US-0225214.
PR   14-AUG-2000; 2000US-0225266.
PR   14-AUG-2000; 2000US-0225267.
PR   14-AUG-2000; 2000US-0225268.
PR   14-AUG-2000; 2000US-0225270.
PR   14-AUG-2000; 2000US-0225447.
PR   14-AUG-2000; 2000US-0225757.
PR   14-AUG-2000; 2000US-0225758.
PR   14-AUG-2000; 2000US-0225759.
PR   18-AUG-2000; 2000US-0226279.
PR   22-AUG-2000; 2000US-0226681.
PR   22-AUG-2000; 2000US-0226868.
PR   22-AUG-2000; 2000US-0227182.
PR   23-AUG-2000; 2000US-0227009.
PR   30-AUG-2000; 2000US-0228924.
PR   01-SEP-2000; 2000US-0229287.
PR   01-SEP-2000; 2000US-0229343.
PR   01-SEP-2000; 2000US-0229344.
PR   01-SEP-2000; 2000US-0229345.
```

PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231988.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234273.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246582.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 05-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM,
XX
DR WPI; 2001-483426/52.
XX
PT Nucleic acids encoding human immune/hematopoietic antigen polypeptides, useful for preventing, diagnosing and/or treating cancers and metastasis -
XX
PS Disclosure; SEQ ID NO 25349; 3071pp + Sequence listing, English.
XX
CC AAK54951 to AAK64702 encode the human immune/haematopoietic antigen (I) amino acid sequences given in AAM82170 to AAM91921. (I) have cytostatic activity, and can be used in gene therapy and vaccine production. (I) proteins and polynucleotides may be used in the prevention, diagnosis and treatment of diseases associated with inappropriate (I) expression. For example, they may be used to treat disorders associated with decreased expression by rectifying mutations or deletions in a patient's genome that affect the activity of (I) by expressing inactive proteins or to supplement the patients own production of (I). Additionally, (I) polynucleotides may be used to produce the secreted (I), by inserting the nucleic acids into a host cell and culturing the cell to express the protein. (I) proteins and polynucleotides may be used to prevent, diagnose and treat immune/haematopoietic-related diseases, especially cancers and cancer metastases of haematopoietic-derived cells. AAK64703 to AAK87634 represent human immune/haematopoietic antigen genomic sequences from the present invention. AAK54942 to AAK54950 and AAM82169 represent sequences used in the exemplification of the present invention.
XX
SQ Sequence 11445 BP; 2857 A; 3157 C; 2738 G; 2743 T; 0 other;

Alignment Scores:
Pred. No.: 9.0269 Length: 11445
Score: 65.00 Matches: 13
Percent Similarity: 100.00% Conservative: 0
Best Local Similarity: 100.00% Mismatches: 0
Query Match: 100.00% Indels: 0
DB: 22 Gaps: 0

US-09-856-070-19 (1-13) x AAK79537 (1-11445)

Qy 1 LysGluGluLeuMetLeuArgLeuGlnAspTyrGluGlu 13
||||||||||||||||||||||||||||||||||||||||||||||
Db 5586 AACGACGACTTCATCCTCCGCCTGCAGGACTATGACGAG 5548

RESULT 11
AAS93352
ID AAS93352 standard; cDNA; 1447 BP.

```
XX
AC   AAS93352;
XX
DT   13-FEB-2002  (first entry)
XX
DE   DNA encoding novel human diagnostic protein #29156.
XX
KW   Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW   food supplement; medical imaging; diagnostic; genetic disorder; ss.
XX
OS   Homo sapiens.
XX
PN   WO200175067-A2.
XX
PD   11-OCT-2001.
XX
PF   30-MAR-2001; 2001WO-US08631.
XX
PR   31-MAR-2000; 2000US-0540217.
PR   23-AUG-2000; 2000US-0649167.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Drmanac RT,  Liu C,  Tang YT;
XX
DR   WPI; 2001-639362/74.
DR   P-PSDB; AAG29165.
XX
PT   New isolated polynucleotide and encoded polypeptides, useful in
PT   diagnostics, forensics, gene mapping, identification of mutations
PT   responsible for genetic disorders or other traits and to assess
PT   biodiversity
XX
PS   Claim 1; SEQ ID No 29156; 193pp; English.
XX
CC   The invention relates to isolated polynucleotide (I) and
CC   polypeptide (II) sequences. (I) is useful as hybridisation probes,
CC   polymerase chain reaction (PCR) primers, oligomers, and for chromosome
CC   and gene mapping, and in recombinant production of (II). The
CC   polynucleotides are also used in diagnostics as expressed sequence tags
CC   for identifying expressed genes. (I) is useful in gene therapy techniques
CC   to restore normal activity of (II) or to treat disease states involving
CC   (II). (II) is useful for generating antibodies against it, detecting or
CC   quantitating a polypeptide in tissue, as molecular weight markers and as
CC   a food supplement. (II) and its binding partners are useful in medical
CC   imaging of sites expressing (II). (I) and (II) are useful for treating
CC   disorders involving aberrant protein expression or biological activity.
CC   The polypeptide and polynucleotide sequences have applications in
CC   diagnostics, forensics, gene mapping, identification of mutations
CC   responsible for genetic disorders or other traits to assess biodiversity
CC   and to produce other types of data and products dependent on DNA and
CC   amino acid sequences. AAS64197-AAS94564 represent novel human
CC   diagnostic coding sequences of the invention.
CC   Note: The sequence data for this patent did not appear in the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 1447 BP; 347 A; 356 C; 383 G; 361 T; 0 other;

Alignment Scores:
Pred. No.:                139             Length:         1447
Score:                    41.00           Matches:        8
Percent Similarity:       90.91%          Conservative:   2
Best Local Similarity:    72.73%          Mismatches:     1
Query Match:              63.08%          Indels:         0
DB:                       23              Gaps:           0

US-09-856-070-19 (1-13) x AAS93352 (1-1447)

Qy       2 GluGluLeuMetLeuArgLeuGlnAspTyrGlu 12
           :::|||||||||||||||   :::||||||||||
Db     979 AAAGAGTTGATGCTACGGCAGAAGGATTACGAG 1011
```

```
RESULT 12
ABQ88140/c
ID   ABQ88140 standard; cDNA; 66494 BP.
XX
AC   ABQ88140;
XX
DT   18-SEP-2002  (first entry)
XX
DE   Human osteoblast differentiation related cDNA SEQ ID NO 47.
XX
KW   Human; osteoblast; stem cell differentiation; bone tissue deposition;
KW   osteoporosis; osteopathic; ss.
XX
OS   Homo sapiens.
XX
PN   WO200250301 A2.
XX
PD   27-JUN-2002.
XX
PF   18-DEC-2001; 2001WO-US48276.
XX
PR   18-DEC-2000; 2000US-255882P.
PR   24-APR-2001; 2001US-285691P.
XX
PA   (GENE-) GENE LOGIC INC.
PA   (PROC ) PROCTER & GAMBLE CO.
XX
PI   Ji D,  Axelrod DW,  Cook JS,  Jaiswal N,  Einstein R,  Houghton A;
PI   Mertz L;
XX
DR   WPI; 2002-557663/59.
XX
PT   Use of genes and their expression profiles associated with osteoblast
PT   differentiation for screening modulators bone formation, for diagnosing
PT   or treating e.g. osteoporosis, or as markers for the differentiation
PT   process
XX
PS   Claim 1; SEQ ID NO 47; 78pp + Sequence Listing; English.
XX
CC   The invention relates to genes and their expression profiles are used
CC   for:
CC   (a) screening modulators of precursor stem cell differentiation into
CC   osteoblasts, or bone tissue deposition;
CC   (b) diagnosing abnormal deposition of bone tissue, abnormal rate of
CC   osteoblast formation or osteoporosis; or
CC   (c) treating or monitoring treatment of the conditions cited in (b), or
CC   monitoring the progression of bone tissue deposition.
CC   Specific conditions include postmenopausal osteoporosis, glucocorticoid
CC   osteoporosis or male osteoporosis, osteopenia, osteodystrophy,
CC   drug-induced abnormalities in bone formation or bone loss, conditions
CC   that involve altered bone metabolism (e.g. idiopathic juvenile
CC   osteoporosis), skeletal disease linked to breast cancer, mastocytosis,
CC   Panconi syndrome or fibrous dysplasia. The present sequence is that of an
CC   osteoblast differentiation associated cDNA marker of the invention.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 66494 BP; 17680 A; 13908 C; 14466 G; 20440 T; 0 other;

Alignment Scores:
Pred. No.:                1.24e+04        Length:         66494
Score:                    41.00           Matches:        8
Percent Similarity:       84.62%          Conservative:   3
Best Local Similarity:    61.54%          Mismatches:     2
Query Match:              63.08%          Indels:         0
DB:                       24              Gaps:           0

US-09-856-070-19 (1-13) x ABQ88140 (1-66494)

Qy       1 LysGluGluLeuMetLeuArgLeuGlnAspTyrGluGlu 13
           |||||||:::|||   |||:::   |||||||||:::|||
Db   57190 AAAGAGCAACTAGGACTTAAGAGACAAGATTATAAAGAG 57152
```

RESULT 13
ABA74089/c
ID ABA74089 standard; DNA; 224 BP.
XX
AC ABA74089;
XX
DT 01-FEB-2002 (first entry)
XX
DE Human foetal liver single exon nucleic acid probe #22394
XX
KW Human; foetal liver; gene expression; single exon nucleic acid probe; ss.
XX
OS Homo sapiens.
XX
PN WO200157277-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US00669
XX
PR 04-FEB-2000; 2000US-0180312.
PR 26-MAY-2000; 2000US-0207456.
PR 30-JUN-2000; 2000US-0608408.
PR 03-AUG-2000; 2000US-0632366.
PR 21-SEP-2000; 2000US-0234687.
PR 27-SEP-2000; 2000US-0236359.
PR 04-OCT-2000; 2000GB-0024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-483447/52.
XX
PT Human genome-derived single exon nucleic acid probes useful for
PT analyzing gene expression in human fetal liver -
XX
PS Claim 4; SEQ ID NO 22394; 639pp + sequence listing, English.
XX
CC The invention relates to a single exon nucleic acid probe for
CC measuring human gene expression in a sample derived from human foetal
CC liver. The single exon nucleic acid probes may be used for predicting,
CC measuring and displaying gene expression in samples derived from human
CC fetal liver. The present sequence is a single exon nucleic acid
CC probe of the invention
CC Note: The sequence data for this patent did not form part of the
CC printed specification, but was obtained in electronic format directly
CC from WIPO at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 224 BP; 58 A; 63 C; 45 G; 58 T; 0 other;

Alignment Scores:

Pred. No.:	24.6	Length:	224
Score:	40.00	Matches:	7
Percent Similarity:	84.62%	Conservative:	4
Best Local Similarity:	53.85%	Mismatches:	2
Query Match:	61.54%	Indels:	0
DB:	22	Gaps:	0

US-09-856-070-19 (1-13) x ABA74089 (1-224)

```
Qy       1 LysGluGluLeuMetLeuArgLeuGlnAspTyrGluGlu 13
           |||:::   |||:::|||   |||:::::|||||||||
Db      57 AAGCAGAATCTGTTGCTGGAACTCCGTAACTATGAGGAA 19
```

RESULT 14
AAK22545/c
ID AAK22545 standard; DNA; 224 BP.
XX
AC AAK22545;
XX
DT 05-NOV-2001 (first entry)
XX
DE Human brain expressed single exon probe SEQ ID NO: 22536.
XX
KW Human, brain expressed exon, gene expression analysis; probe;
KW microarray; Alzheimer's disease; multiple sclerosis; schizophrenia;
KW epilepsy; cancer; ss.
XX
OS Homo sapiens.
XX
PN WO200157275-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US00667.
XX
PR 04-FEB-2000; 2000US-0180312.
PR 26-MAY-2000; 2000US-0207456.
PR 30-JUN-2000; 2000US-0608408.
PR 03-AUG-2000; 2000US-0632366.
PR 21-SEP-2000; 2000US-0234687.
PR 27-SEP-2000; 2000US-0236359.
PR 04-OCT-2000; 2000GB-0024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-483446/52.
XX
PT Single exon nucleic acid probes for analyzing gene expression in human
PT brains -
XX
PS Example 4; SEQ ID NO 22536; 650pp + Sequence Listing, English.
XX
CC The present invention provides a number of single exon nucleic acid
CC probes which are derived from genomic sequences expressed in the human
CC brain. They can be used to measure gene expression in brain cell samples,
CC which may enable the diagnosis and improved treatment of nervous system
CC diseases such as Alzheimer's disease, multiple sclerosis, schizophrenia,
CC epilepsy and cancers. The present sequence is one of the probes of the
CC invention.
XX
SQ Sequence 224 BP; 58 A; 63 C; 45 G; 58 T; 0 other;

Alignment Scores:

Pred. No.:	24.6	Length:	224
Score:	40.00	Matches:	7
Percent Similarity:	84.62%	Conservative:	4
Best Local Similarity:	53.85%	Mismatches:	2
Query Match:	61.54%	Indels:	0
DB:	22	Gaps:	0

US-09-856-070-19 (1-13) x AAK22545 (1-224)

```
Qy       1 LysGluGluLeuMetLeuArgLeuGlnAspTyrGluGlu 13
           |||:::   |||:::|||   |||:::::|||||||||
Db      57 AAGCAGAATCTGTTGCTGGAACTCCGTAACTATGAGGAA 19
```

RESULT 15
ABA61592/c
ID ABA61592 standard; DNA; 520 BP.
XX
AC ABA61592;
XX
DT 01-FEB-2002 (first entry)
XX
DE Human foetal liver single exon nucleic acid probe #9897.
XX
KW Human, foetal liver, gene expression, single exon nucleic acid probe; ss.
XX
OS Homo sapiens.
XX
PN WO200157277-A2.

XX
PD 09 AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US00669.
XX
PR 04-FEB-2000; 2000US-0180312.
PR 26-MAY-2000; 2000US-0207456.
PR 30-JUN-2000; 2000US-0608408.
PR 03-AUG-2000; 2000US-0632366.
PR 21-SEP-2000; 2000US-0234687.
PR 27-SEP-2000; 2000US-0236359.
PR 04-OCT-2000; 2000GB-0024263.
XX
PA (MOLE) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-483447/52.
XX
PT Human genome-derived single exon nucleic acid probes useful for
PT analyzing gene expression in human fetal liver -
XX
PS Claim 1; SEQ ID NO 9897; 639pp + sequence listing; English.
XX
CC The invention relates to a single exon nucleic acid probe for
CC measuring human gene expression in a sample derived from human foetal
CC liver. The single exon nucleic acid probes may be used for predicting,
CC measuring and displaying gene expression in samples derived from human
CC fetal liver. The present sequence is a single exon nucleic acid
CC probe of the invention.
CC Note: The sequence data for this patent did not form part of the
CC printed specification, but was obtained in electronic format directly
CC from WIPO at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 520 BP; 135 A; 145 C; 88 G; 152 T; 0 other;

Alignment Scores:

Pred. No.:	66.1	Length:	520
Score:	40.00	Matches:	7
Percent Similarity:	84.62%	Conservative:	4
Best Local Similarity:	53.85%	Mismatches:	2
Query Match:	61.54%	Indels:	0
DB:	22	Gaps:	0

US-09-856-070-19 (1-13) x ABA61592 (1-520)

```
Qy       1 LysGluGluLeuMetLeuArgLeuGlnAspTyrGluGlu 13
           ||:::  |||:::|||  |||:::::|||||||||
Db     150 AAGCAGAATCTGTTGCTCGAACTCCGTAACTATGAGGAA 112
```

Search completed: January 16, 2003, 17:19:45
Job time : 218.954 secs